Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145

Trial Profile

A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2019

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Adverse reactions
  • Acronyms OSLER-2; PROFICIO
  • Sponsors Amgen
  • Most Recent Events

    • 29 Mar 2019 Results (n=556) evaluating safety and efficacy results of evolocumab in japanese patients of the OSLER studies published in the Circulation Journal
    • 14 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 13 Jun 2018 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top